regenerative    medicine,cartilage: bronchus repair using    bioartificial tissue transplantationHospital Clinic of    Barcelona/APthe application of    treatments developed to replace tissues    damaged by injury or disease. These treatments may involve the    use of biochemical techniques to induce tissue     regeneration directly at the site of damage or the    use of transplantation techniques employing differentiated        cells or stem    cells, either alone or as part of a bioartificial    tissue. Bioartificial tissues are made by seeding cells onto    natural or biomimetic    scaffolds    (see     tissue engineering). Natural scaffolds are the total    extracellular    matrixes (ECMs) of decellularized tissues or    organs.    In contrast, biomimetic scaffolds may be composed of natural    materials, such as collagen    or proteoglycans (proteins    with long chains of     carbohydrate), or built from artificial materials,    such as     metals,     ceramics, or     polyester polymers. Cells used for transplants and    bioartificial tissues are almost always autogeneic (self) to    avoid rejection by the patients     immune system. The use of allogeneic (nonself) cells    carries a high risk of immune rejection and therefore requires    tissue matching between donor and recipient and involves the    administration of immunosuppressive     drugs.  
    A variety of autogeneic and allogeneic cell and bioartificial    tissue transplantations    have been performed. Examples of autogeneic transplants using    differentiated cells include     blood transfusion with frozen stores of the    patients own     blood and repair of the articular cartilage    of the     knee with the patients own articular chondrocytes    (cartilage cells) that have been expanded in vitro (amplified    in number using     cell culture techniques in a laboratory). An example    of a tissue that has been generated for autogeneic        transplant is the human mandible (lower        jaw). Functional bioartificial mandibles are made by    seeding autogeneic     bone marrow cells onto a     titanium mesh scaffold loaded with bovine bone    matrix, a type of extracellular matrix that has proved valuable    in regenerative medicine for its ability to promote cell    adhesion and proliferation in transplantable     bone tissues. Functional bioartificial     bladders also have been successfully implanted into    patients. Bioartificial bladders are made by seeding a    biodegradable polyester scaffold with autogeneic urinary    epithelial cells and smooth     muscle cells.  
    Another example of a tissue used successfully in an autogeneic    transplant is a bioartificial bronchus, which was generated to    replace damaged tissue in a patient affected by     tuberculosis. The bioartificial bronchus was    constructed from an ECM scaffold of a section of bronchial    tissue taken from a donor cadaver. Differentiated epithelial    cells isolated from the patient and chondrocytes derived from    mesenchymal stem cells collected from the patients bone marrow    were seeded onto the scaffold.  
    There are few clinical examples of allogeneic cell and    bioartificial tissue transplants. The two most common    allogeneic transplants are     blood-group-matched     blood transfusion and     bone marrow transplant. Allogeneic bone marrow    transplants are often performed following high-dose        chemotherapy, which is used to destroy all the cells    in the hematopoietic system in order to ensure that all        cancer-causing cells are killed. (The hematopoietic    system is contained within the bone marrow and is responsible    for generating all the cells of the blood and immune system.)    This type of bone marrow transplant is associated with a high    risk of graft-versus-host    disease, in which the donor marrow cells attack the    recipients tissues. Another type of allogeneic transplant    involves the islets of Langerhans, which contain the        insulin-producing cells of the body. This type of    tissue can be transplanted from cadavers    to patients with     diabetes mellitus, but recipients require    immunosuppression therapy to survive.  
    Cell transplant experiments with paralyzed mice, pigs, and    nonhuman primates demonstrated that     Schwann cells (the     myelin-producing cells that insulate nerve        axons) injected into acutely injured spinal cord    tissue could restore about 70 percent of the tissues    functional capacity, thereby partially reversing     paralysis.  
    embryonic stem cell: scientists    conducting research on embryonic stem cellsMauricio LimaAFP/Getty    ImagesStudies on experimental animals    are aimed at understanding ways in which autogeneic or    allogeneic adult stem cells can be used to regenerate damaged    cardiovascular, neural, and musculoskeletal tissues in humans.    Among adult stem cells that have shown promise in this area are    satellite cells, which occur in skeletal muscle fibres in    animals and humans. When injected into mice affected by    dystrophy, a condition characterized by the progressive    degeneration of muscle tissue, satellite cells stimulate the    regeneration of normal muscle fibres. Ulcerative colitis in    mice was treated successfully with intestinal organoids    (organlike tissues) derived from adult stem cells of the large    intestine. When introduced into the colon, the organoids    attached to damaged tissue and generated a normal-appearing    intestinal lining.  
    In many cases, however, adult stem cells such as satellite    cells have not been easily harvested from their native tissues,    and they have been difficult to culture in the laboratory. In    contrast, embryonic    stem cells (ESCs) can be harvested once and cultured    indefinitely. Moreover, ESCs are pluripotent, meaning that they    can be directed to differentiate into any cell type, which    makes them an ideal cell source for regenerative medicine.  
    Studies of animal ESC derivatives have demonstrated that these    cells are capable of regenerating tissues of the central        nervous system,     heart, skeletal muscle, and     pancreas. Derivatives of human ESCs used in animal    models have produced similar results. For example, cardiac stem    cells from     heart-failure patients were engineered to express a    protein (Pim-1) that promotes cell survival and proliferation.    When these cells were injected into mice that had experienced    myocardial infarction (heart    attack), the cells were found to enhance the repair    of injured heart muscle tissue. Likewise, heart muscle cells    (cardiomyocytes) derived from human ESCs improved the function    of injured heart muscle tissue in guinea pigs.  
    Derivatives of human ESCs are likely to produce similar results    in humans, although these cells have not been used clinically    and could be subject to immune rejection by recipients. The    question of immune rejection was bypassed by the discovery in    2007 that adult somatic cells (e.g., skin and liver cells) can    be converted to ESCs. This is accomplished by transfecting    (infecting) the adult cells with viral vectors carrying        genes that encode     transcription factor proteins    capable of reprogramming the adult cells into pluripotent stem    cells. Examples of these factors include Oct-4 (octamer 4),    Sox-2 (sex-determining region Y box 2), Klf-4 (Kruppel-like    factor 4), and Nanog. Reprogrammed adult cells, known as    induced    pluripotent stem (iPS) cells, are potential    autogeneic sources for cell transplantation and bioartificial    tissue construction. Such cells have since been created from    the skin cells of patients suffering from     amyotrophic lateral sclerosis (ALS) and        Alzheimer disease and have been used as human models    for the exploration of disease mechanisms and the screening of    potential new drugs. In one such model, neurons derived from    human iPS cells were shown to promote recovery of     stroke-damaged brain tissue in mice and rats,
 and,    in another, cardiomyocytes derived from human iPS cells    successfully integrated into damaged heart tissue following    their     injection into rat hearts. These successes indicated    that iPS cells could serve as a cell source for tissue    regeneration or bioartificial tissue construction.  
    Scaffolds    and soluble factors, such as proteins and small molecules, have    been used to induce tissue repair by undamaged cells at the    site of injury. These agents protect resident     fibroblasts and adult stem cells and stimulate the    migration of these cells into damaged areas, where they    proliferate to form new tissue. The ECMs of pig small intestine    submucosa, pig and human     dermis, and different types of biomimetic scaffolds    are used clinically for the repair of     hernias, fistulas (abnormal ducts or passageways    between organs), and     burns.  
See the original post:
regenerative medicine | Britannica.com